In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ross Labs

This article was originally published in The Tan Sheet

Executive Summary

Abbott Senior VP-Finance and Chief Financial Officer Gary Coughlan tells May 10 session at Alex. Brown investment conference that the company's nutrition R&D is "focusing on improved pediatric formulas, new disease-specific products" like the medical nutritional Advera, and "new packages and systems" for existing products. He noted that the company's medical nutritional sales increased 15% in 1993 to $850 mil., and that Abbott maintains its leadership position in hospitals, nursing homes and retail outlets





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts